Likidia stock up 11% on patent deal

Lycadia announced the signing of a patent agreement with Union Therapeutics, ensuring continued supply of the medication YUTREPIA for the treatment of pulmonary arterial hypertension. Following this, the company's stock surged by 11%. This deal highlights the importance of intellectual property protection to ensure the distribution of vital medicines and the company's sustainable financial future.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل